2-(6-chloro-1H-indol-3-yl)-N,N-dimethylethylamine | 25390-72-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(6-chloro-1H-indol-3-yl)-N,N-dimethylethylamine
• 英文别名: 6-Chlor-N-N-dimethyl-tryptamin；[2-(6-chloro-indol-3-yl)-ethyl]-dimethyl-amine；Indole, 6-chloro-3-((dimethylamino)ethyl)-；2-(6-chloro-1H-indol-3-yl)-N,N-dimethylethanamine
• CAS: 25390-72-1
• 化学式: C₁₂H₁₅ClN₂
• 分子量: 222.718
• InChiKey: ISARSRVZSPZICH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  19
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-溴噻唑-4-甲酸乙酯 、 2-(6-chloro-1H-indol-3-yl)-N,N-dimethylethylamine 在 copper(l) iodide 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 potassium phosphate 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping

  摘要：

  We describe the medicinal chemistry approach that generated a novel indole series of EP1 receptor antagonists. The SAR of this new template was evaluated and culminated in the identification of compound 12g which demonstrated in vivo efficacy in a preclinical model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.018
• 作为产物：
  描述：

  6-Chlor-indolyl-3-glyoxal-dimethylamid 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-(6-chloro-1H-indol-3-yl)-N,N-dimethylethylamine
  参考文献：
  名称：

  Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping

  摘要：

  We describe the medicinal chemistry approach that generated a novel indole series of EP1 receptor antagonists. The SAR of this new template was evaluated and culminated in the identification of compound 12g which demonstrated in vivo efficacy in a preclinical model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.03.018

文献信息

• 吲哚衍生物及其在药物上的应用
  申请人：广东东阳光药业有限公司

  公开号：CN104276993B

  公开（公告）日：2019-03-15

  本发明提供一些吲哚衍生物或其立体异构体，互变异构体，氮氧化物，溶剂化物，代谢产物，药学上可接受的盐或前药，用于治疗阿尔茨海默症。本发明还公开了含有这样的化合物的药物组合物和使用本发明化合物或其药物组合物治疗阿尔茨海默症的方法。
• [EN] INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS<br/>[FR] DERIVES D'INDOLINE UTILISES COMME LIGANDS DES RECEPTEURS 5-HT2B ET/OU 5-HT2C
  申请人：CEREBRUS PHARM LTD

  公开号：WO2000012475A1

  公开（公告）日：2000-03-09

  For use in therapy a chemical compound of formula (I), wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, heterocyclyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, wherein at least one of R4 to R7 is a substituent group other than hydrogen, and pharmaceutically acceptable salts and prodrugs thereof, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and especially for the treatment of obesity; chemical compounds of formula (I) other than compounds wherein R7 is hydroxy.

  用于治疗的化合物的化学式（I），其中R1至R3分别选择氢和烷基；R4至R7分别选择氢，卤素，羟基，烷基，芳基，杂环基，烷氧基，芳氧基，烷硫基，芳硫基，烷基亚砜基，烷基磺酰基，芳基亚砜基，芳基磺酰基，氨基，单烷基氨基，双烷基氨基，硝基，氰基，羰基，烷基羰基，芳基羰基，氨基羰基，单烷基氨基羰基，双烷基氨基羰基，烷氧羰基氨基，氨基羟基羰基氧基，单烷基氨基羟基羰基氧基，双烷基氨基羟基羰基氧基，单烷基氨基羰基氧基和双烷基氨基羰基氧基，其中R4至R7中至少有一个是除氢外的取代基团，以及其药学上可接受的盐和前药，特别用于治疗中枢神经系统紊乱，中枢神经系统损伤，心血管疾病，胃肠道疾病，尿崩症和睡眠呼吸暂停，尤其用于治疗肥胖症；化学式（I）的化合物，除了其中R7为羟基的化合物。
• INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS
  申请人：VERNALIS RESEARCH LIMITED

  公开号：EP1109784A1

  公开（公告）日：2001-06-27
• Discovery of a novel indole series of EP1 receptor antagonists by scaffold hopping
  作者：Adrian Hall、Andy Billinton、Susan H. Brown、Anita Chowdhury、Gerard M.P. Giblin、Paul Goldsmith、David N. Hurst、Alan Naylor、Sadhana Patel、Tiziana Scoccitti、Pamela J. Theobald

  DOI：10.1016/j.bmcl.2008.03.018

  日期：2008.4

  We describe the medicinal chemistry approach that generated a novel indole series of EP1 receptor antagonists. The SAR of this new template was evaluated and culminated in the identification of compound 12g which demonstrated in vivo efficacy in a preclinical model of inflammatory pain. (C) 2008 Elsevier Ltd. All rights reserved.